This observational study will evaluate the safety, tolerability and efficacy of RoActemra/Actemra in patients with moderate to severe rheumatoid arthritis who have an inadequate response to current non-biologic DMARD and/or anti-TNF therapy. Data will be collected from each patient during RoActemra/Actemra therapy and on follow-up for a total of 12 months.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01362062?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
